Altimmune
ALT
173 hedge funds and large institutions have $214M invested in Altimmune in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 82 increasing their positions, 34 reducing their positions, and 33 closing their positions.
225% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $3.21M
141% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 34
8% more capital invested
Capital invested by funds: $198M → $214M (+$15.5M)
0.76% more ownership
Funds ownership: 52.56% → 53.32% (+0.76%)
9% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 33
4% less funds holding
Funds holding: 181 → 173 (-8)
Top Buyers
| 1 |
Marshall Wace
London,
United Kingdom
|
+$13.1M |
| 2 |
BlackRock
New York
|
+$13.1M |
| 3 |
Millennium Management
New York
|
+$13M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$11.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.6M |
Top Sellers
| 1 |
Jane Street
New York
|
-$7.57M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$6.22M |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$4.08M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.77M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.62M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$903 | -250 | Closed |
|
202
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -235 | Closed |
|
|
TPCW
203
TD Private Client Wealth
New York
| – | -$697 | -193 | Closed |
|
|
LI
204
LRI Investments
Palm Beach Gardens,
Florida
| – | -$444 | -123 | Closed |
|
|
CRI
205
Commonwealth Retirement Investments
Richmond,
Virginia
| – | -$4 | -1 | Closed |
|
|
CPG
206
Cornerstone Planning Group
Fairfield,
New Jersey
| – | -$5 | -1 | Closed |
|
ALT Hedge Fund Activity: Q1 2026 in Review
173 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2026, worth a combined $214M — up 7.8% from $198M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of ALT and 30 opened new positions — a net loss of 3 holders — while 34 trimmed existing stakes and 82 added.
The largest buyer was Marshall Wace, adding an estimated $13.1M. The largest seller was Jane Street, exiting entirely with an estimated $7.57M sold.
- 173 institutional investors held Altimmune (ALT) as of Q1 2026, down from 181 in Q4 2025.
- Funds reported $214M of Altimmune stock for Q1 2026, up 7.8% quarter-over-quarter.
- 30 funds opened new Altimmune positions in Q1 2026 and 33 closed out, a net change of -3 holders.
- The largest Altimmune buyer in Q1 2026 was Marshall Wace, an estimated $13.1M added.
- The largest Altimmune seller in Q1 2026 was Jane Street, an estimated $7.57M sold.
Based on aggregated 13F filings for Q1 2026.